AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
WEST LAFAYETTE, Ind., Nov. 09, 2017 -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the Jefferies 2017 London Healthcare Conference on Wednesday, Nov. 15, 2017, at 8:40 a.m. GMT.
A live audio webcast of the Company’s presentation can be accessed by visiting “Events & Presentations” under the Investors & News section of Endocyte’s website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company’s website for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. Endocyte uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The company’s agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate-specific membrane antigen (PSMA) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
